The estimated Net Worth of Joseph H. Reilly is at least $93.4 ezer dollars as of 14 December 2020. Mr. Reilly owns over 8,750 units of Minerva Neurosciences Inc stock worth over $93,383 and over the last 10 years he sold NERV stock worth over $0. In addition, he makes $0 as Chief Operating Officer és Senior Vice President at Minerva Neurosciences Inc.
Joseph has made over 6 trades of the Minerva Neurosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 8,750 units of NERV stock worth $23,363 on 14 December 2020.
The largest trade he's ever made was exercising 25,000 units of Minerva Neurosciences Inc stock on 1 October 2018 worth over $122,500. On average, Joseph trades about 4,840 units every 147 days since 2014. As of 14 December 2020 he still owns at least 34,975 units of Minerva Neurosciences Inc stock.
You can see the complete history of Mr. Reilly stock trades at the bottom of the page.
Joseph Reilly serves as Chief Operating Officer, Senior Vice President of the Company. Mr. Reilly has provided services to us since January 2014 and was named our Chief Operating Officer in July 2014. Mr. Reilly was named Senior Vice President in May 2015. Prior to joining us, Mr. Reilly served as Vice President and Head of Commercial Strategy and Operations at Genzyme Corporation, a Sanofi pharmaceutical company, from August 2012 to December 2013. He earned his B.S. in Finance at Boston College and his M.S. in Finance from the Wallace E. Carroll Graduate School of Management at Boston College.
Joseph Reilly is 45, he's been the Chief Operating Officer és Senior Vice President of Minerva Neurosciences Inc since 2015. There are 20 older and no younger executives at Minerva Neurosciences Inc. The oldest executive at Minerva Neurosciences Inc is David Kupfer, 79, who is the Independent Director.
Joseph's mailing address filed with the SEC is C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM, MA, 02451.
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over $49,043,620 worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth $47,876,311 . The most active insiders traders include & Johnson Johnson & Johnson..., Venture Associates Iii Ltd ... és Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $556,476. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth $105,193.
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include: